NO20025999D0 - Klart, vandig anestetisk preparat - Google Patents
Klart, vandig anestetisk preparatInfo
- Publication number
- NO20025999D0 NO20025999D0 NO20025999A NO20025999A NO20025999D0 NO 20025999 D0 NO20025999 D0 NO 20025999D0 NO 20025999 A NO20025999 A NO 20025999A NO 20025999 A NO20025999 A NO 20025999A NO 20025999 D0 NO20025999 D0 NO 20025999D0
- Authority
- NO
- Norway
- Prior art keywords
- propofol
- compositions
- clear
- hydroxypropyl
- beta
- Prior art date
Links
- 230000003444 anaesthetic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical group CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 abstract 3
- 229960004134 propofol Drugs 0.000 abstract 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 2
- 229940124326 anaesthetic agent Drugs 0.000 abstract 1
- 239000003193 general anesthetic agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN573MU2000 IN187686B (cs) | 2000-06-21 | 2000-06-21 | |
| PCT/IN2000/000124 WO2001097796A1 (en) | 2000-06-21 | 2000-12-14 | Clear aqueous anaesthetic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20025999L NO20025999L (no) | 2002-12-13 |
| NO20025999D0 true NO20025999D0 (no) | 2002-12-13 |
Family
ID=11097257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025999A NO20025999D0 (no) | 2000-06-21 | 2002-12-13 | Klart, vandig anestetisk preparat |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7138387B2 (cs) |
| EP (1) | EP1299095B1 (cs) |
| JP (1) | JP4907833B2 (cs) |
| KR (1) | KR100810066B1 (cs) |
| CN (1) | CN1254237C (cs) |
| AP (1) | AP2002002674A0 (cs) |
| AT (1) | ATE267592T1 (cs) |
| AU (2) | AU2001235972B2 (cs) |
| BG (1) | BG107463A (cs) |
| BR (1) | BR0017268A (cs) |
| CA (1) | CA2414064C (cs) |
| DE (1) | DE60011149T2 (cs) |
| DK (1) | DK1299095T3 (cs) |
| EA (1) | EA005589B1 (cs) |
| ES (1) | ES2222271T3 (cs) |
| HU (1) | HUP0301646A3 (cs) |
| IL (1) | IL153387A0 (cs) |
| IN (1) | IN187686B (cs) |
| MX (1) | MXPA02012611A (cs) |
| NO (1) | NO20025999D0 (cs) |
| NZ (1) | NZ523643A (cs) |
| PL (1) | PL359624A1 (cs) |
| PT (1) | PT1299095E (cs) |
| WO (1) | WO2001097796A1 (cs) |
| YU (1) | YU2703A (cs) |
| ZA (1) | ZA200300336B (cs) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN188917B (cs) * | 2000-12-07 | 2002-11-23 | Bharat Surums & Vaccines Ltd | |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| CN1329036C (zh) * | 2001-12-28 | 2007-08-01 | Mgigp公司 | 普鲁泊福水溶性前药的以水为基质的药物制剂 |
| EP1469886B8 (en) * | 2002-02-01 | 2008-01-09 | Shimoda Biotech (PTY) LTD | Lyophilized pharmaceutical composition of propofol |
| JP2005538191A (ja) * | 2002-07-29 | 2005-12-15 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 水性２，６―ジイソプロピルフェノール医薬組成物 |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| KR20200083657A (ko) * | 2002-12-09 | 2020-07-08 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| US20090192230A1 (en) * | 2004-01-14 | 2009-07-30 | Koichi Takeda | Propofol-containing fat emulsion preparation |
| KR20070058608A (ko) * | 2004-09-13 | 2007-06-08 | 바라트 쎄럼스 앤드 백신스 리미티드 | 항미생물 방부 효능을 갖는 정맥 내 투여를 위한 안정한에멀젼 조성물 |
| EA014673B1 (ru) * | 2005-08-12 | 2010-12-30 | Бхарат Сирумс Энд Вэксинс Лтд. | Водные анестезирующие композиции, содержащие пропофол |
| WO2007128866A2 (en) * | 2006-05-09 | 2007-11-15 | Novobion Oy | Novel chemical compositions |
| EP2712900A1 (en) * | 2008-03-11 | 2014-04-02 | 3M Innovative Properties Company | Phototools having a protective layer |
| WO2010148288A2 (en) * | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
| EP2456823A4 (en) | 2009-07-21 | 2012-12-26 | 3M Innovative Properties Co | CURABLE COMPOSITION, METHOD FOR COATING A PHOTO TOOL, AND COATED PHOTO TOOL |
| WO2011034845A1 (en) | 2009-09-16 | 2011-03-24 | 3M Innovative Properties Company | Fluorinated coating and phototools made therewith |
| CN102686642B (zh) | 2009-09-16 | 2016-06-29 | 3M创新有限公司 | 氟化涂料和用其制作的底片 |
| US8268067B2 (en) * | 2009-10-06 | 2012-09-18 | 3M Innovative Properties Company | Perfluoropolyether coating composition for hard surfaces |
| EP2345427A1 (de) * | 2010-01-14 | 2011-07-20 | SapioTec GmbH | Flurankomplex |
| DK2484350T3 (en) * | 2011-02-04 | 2016-08-01 | Norbert Univ -Prof Dr Med Roewer | A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt |
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| US9492552B2 (en) * | 2011-11-29 | 2016-11-15 | Jurox Pty Ltd | Injectable aqueous pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative |
| CN103263404B (zh) * | 2012-04-28 | 2017-12-01 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种复合麻醉药物 |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| US10646439B2 (en) * | 2016-01-29 | 2020-05-12 | Cuda Anesthetics, Llc | Aqueous pharmaceutical formulation comprising propofol |
| FR3117337B1 (fr) | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
-
2000
- 2000-06-21 IN IN573MU2000 patent/IN187686B/en unknown
- 2000-12-14 AT AT00991825T patent/ATE267592T1/de active
- 2000-12-14 WO PCT/IN2000/000124 patent/WO2001097796A1/en not_active Ceased
- 2000-12-14 ES ES00991825T patent/ES2222271T3/es not_active Expired - Lifetime
- 2000-12-14 PL PL00359624A patent/PL359624A1/xx unknown
- 2000-12-14 PT PT00991825T patent/PT1299095E/pt unknown
- 2000-12-14 IL IL15338700A patent/IL153387A0/xx not_active IP Right Cessation
- 2000-12-14 KR KR1020027017362A patent/KR100810066B1/ko not_active Expired - Fee Related
- 2000-12-14 CA CA2414064A patent/CA2414064C/en not_active Expired - Fee Related
- 2000-12-14 HU HU0301646A patent/HUP0301646A3/hu unknown
- 2000-12-14 DK DK00991825T patent/DK1299095T3/da active
- 2000-12-14 NZ NZ523643A patent/NZ523643A/en not_active IP Right Cessation
- 2000-12-14 EP EP00991825A patent/EP1299095B1/en not_active Expired - Lifetime
- 2000-12-14 YU YU2703A patent/YU2703A/sh unknown
- 2000-12-14 BR BR0017268-5A patent/BR0017268A/pt not_active Application Discontinuation
- 2000-12-14 JP JP2002503273A patent/JP4907833B2/ja not_active Expired - Fee Related
- 2000-12-14 AP APAP/P/2002/002674A patent/AP2002002674A0/en unknown
- 2000-12-14 AU AU2001235972A patent/AU2001235972B2/en not_active Ceased
- 2000-12-14 EA EA200300047A patent/EA005589B1/ru not_active IP Right Cessation
- 2000-12-14 CN CNB008198292A patent/CN1254237C/zh not_active Expired - Fee Related
- 2000-12-14 DE DE60011149T patent/DE60011149T2/de not_active Expired - Lifetime
- 2000-12-14 AU AU3597201A patent/AU3597201A/xx active Pending
- 2000-12-14 US US10/296,765 patent/US7138387B2/en not_active Expired - Lifetime
- 2000-12-14 MX MXPA02012611A patent/MXPA02012611A/es active IP Right Grant
-
2002
- 2002-12-13 NO NO20025999A patent/NO20025999D0/no not_active Application Discontinuation
-
2003
- 2003-01-13 ZA ZA200300336A patent/ZA200300336B/en unknown
- 2003-01-16 BG BG107463A patent/BG107463A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20025999D0 (no) | Klart, vandig anestetisk preparat | |
| BR0111206A (pt) | Derivados de arilmetilamina para uso como inibidores de triptase | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| EP1819227A4 (en) | PHARMACEUTICAL FORMULATIONS OF DECITABIN | |
| SE0001899D0 (sv) | New compounds | |
| AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
| MEP36608A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| BRPI0414428A (pt) | composições farmacêuticas | |
| UA91512C2 (ru) | Коньюгати олигомеров инсулина, их композиция (варианты) и применение | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| ECSP066312A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| ECSP078023A (es) | Ingrediente farmacéutico activo en base a canabinoide | |
| BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
| HUT75513A (en) | Taxane class derivative based pharmaceutical compositions and their preparation | |
| ATE430564T1 (de) | Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| ES2105923B1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
| AR028987A1 (es) | Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad | |
| WO2007056263A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously | |
| AR074724A1 (es) | Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno | |
| BR0210063A (pt) | Composição estável e uso da mesma | |
| ATE261732T1 (de) | Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl | |
| BRPI0506710A (pt) | composições farmacêuticas de liberação controlada | |
| AR038017A1 (es) | Composicion anestesica acuosa y clara |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |